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Umbilical cord blood (UCB) transplantation has been consistently found to have low
rates of graft-versus-host disease (GVHD), high rates of engraftment, and faster turnaround
times in terms of finding suitable donors. In addition, it serves as a viable option for
individuals with no matched donor options especially due to its flexible human leukocyte
antigen matching criteria. Despite its advantages, there has been an overall decrease in UCB
transplantation. However, its advantages emphasize the need for further research and
investment in resources such as cord blood banking especially since pediatric populations are
most likely to benefit from continued research due to them typically being the recipients of
UCB transplantation. A retrospective cohort study was conducted to determine if recipients
of a mismatched UCB transplantation were at higher risk of developing acute GVHD and
failure to achieve engraftment. Other risk factors including cytomegalovirus (CMV)
serology status, geographical origin of UCB unit, and primary disease were examined to
determine if they were associated with an increased risk of acute GVHD and failure to
achieve engraftment. The results for the following factors were shown to be not significant
thus not considered as an increased risk of acute GVHD: mismatched cord blood units

according to 6 loci matching criteria (RR 1.09; CI 95%, 0.28-4.24; p = 0.61), mismatched
cord blood units according to 10 loci matching criteria (RR 0.86; CI 95%, 0.19-3.89; p =
0.57), malignant primary disease (RR 2.55; CI 95%, 0.65-9.94; p=0.54), international CBU
origin (RR 0.63; CI 95% 0.08-4.73; p=0.54), and positive donor’s maternal CMV status (RR
0.82; CI 95%, 0.20-3.35; p=0.54). In addition, the following results for potential risk factors
were not significant thus not considered as an increased risk of failure to achieve
engraftment: mismatched cord blood units according to 6 loci matching criteria (RR 1.28; CI
95%, 0.12-13.54; p = 0.66), mismatched cord blood units according to 10 loci matching
criteria (RR 0.56; CI 95%, 0.05-5.86; p = 0.53), and malignant primary disease (RR 0.74; CI
95%, 0.07-7.86; p=0.64). The non-significant results could be contributed to the fact that the
small sample size did not meet the requirement for 80% power. Despite this major limitation,
the study helped further understand how match grade is related to GVHD development
especially since there is a limited number of studies on this topic to begin with. This study
emphasizes the need for further large-scale research to gain a more comprehensive
understanding of UCB transplantation. Further research has implications to improve the
transplant-related diseases in the pediatric populations around the world.
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BACKGROUND
Literature Review
Hematopoietic stem cell (HSC) transplantation is a treatment for specific malignant
diseases, such as acute myeloid leukemia (AML), and specific non-malignant diseases, such
as severe combined immunodeficiency (SCID) (Galgano & Hutt, 2017). There are two types
of transplantation: autologous and allogeneic. The type of transplant chosen depends on the
primary disease and the purpose of the treatment. In autologous transplantation, a patient
serves as their own donor and receives their own HSC. After undergoing high-dose
chemotherapy as treatment for malignancy, patients often experience adverse effects
including chemotherapy-induced bone marrow damage which affects the patient’s ability to
create new blood cells. An autologous stem cell infusion would treat this issue by helping
restore the patient’s HSC. Since an individual is receiving their own cells, there is no risk of
graft-versus-host disease (GVHD). Allogeneic transplantation is used to describe
transplantation that uses HSC derived from a donor (Hatzimichael & Tuthill, 2010). The
purpose of an allogeneic transplantation is to either replace the recipient’s immune system
with the donor’s to help eliminate malignancy in malignant disease or to replace nonfunctional elements of the recipient’s immune system in non-malignant diseases (Galgano &
Hutt, 2017). In an allogeneic transplant, the donor may be syngeneic, related, or unrelated.
Syngeneic is a type of allogeneic transplantation where the donor is the identical twin of the
recipient, thus the recipient and donor are genetically identical with no risk of GVHD
(Hatzimichael & Tuthill, 2010). For both unrelated and related allogeneic transplants, the
recipient and donor are matched according to human leukocyte antigen (HLA) compatibility
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to minimize the risk of GVHD, graft rejection, and other transplant related complications
(Tiercy, 2016).
The transplantation process includes several steps: donor identification, mobilization
and harvesting, conditioning, infusion, neutropenic phase, and recovery and engraftment
(Galgano & Hutt, 2017). The donor identification involves analyzing the HLA compatibility
between the recipient and the donor to determine if they are an ideal match. This process will
be discussed in further detail later. Once a donor is identified, the HSC must be extracted
from an HSC source which includes bone marrow, peripheral blood, or cord blood units
(CBU). Before the actual HSC infusion can occur, the recipient must undergo conditioning
(Khaddour & Mewawalla, 2019). Conditioning is also known as preparative regimen, and
this process includes the recipient undergoing chemotherapy and, depending on primary
disease and treatment protocol, potentially total body irradiation. The purpose of this process
is to eliminate any remaining malignant cells and non-functional hematopoietic cells and
suppress the immune system in order to minimize the risk of graft rejection (Hatzimichael &
Tuthill, 2010). Once conditioning is completed and the HSC is collected and processed based
on specific treatment protocol requirements, it is then infused into the recipient. After
conditioning and infusion, the recipient undergoes a neutropenic phase where their neutrophil
counts and overall blood counts are low (Galgano & Hutt, 2017). At this stage, the recipients
are immunocompromised thus more at risk for infections. In addition, due to low counts of
blood components, including platelets and hemoglobin, they are more susceptible to bleeding
and fatigue. The final step of the transplantation process is recovery and engraftment. A
successful transplantation is determined by the recipient’s ability to accept the donor’s HSC
2

and achieve engraftment (Gonçalves, Benvegnú, & Bonfanti, 2009). A recipient has achieved
engraftment once their neutrophil count has recovered and reached a threshold of >500/µL
cells.
In order to determine if a donor is a suitable match for the recipient, HLA typing is
completed. HLA refers to surface proteins that are located on leukocytes, or white blood
cells, and most other cells (Berger, 2001). These surface proteins play a role in the regulation
of immunological responses (Choo, 2007). The HLA compatibility of the donor and recipient
is thus important because if poorly matched, it could elicit an immunological response that
could lead to graft rejection and other adverse effects including GVHD and even death. HLA
compatibility is determined through the process of HLA typing which involves collecting a
blood sample from both the potential donors and recipient and identifying specific genetic
markers through molecular tests (Berger, 2001). The genetic markers are found across ten
loci on chromosome 6 and are typed to determine HLA compatibility across five antigens: A,
B, C, DRB1, and DQB1 (Mahdi, 2019). The gold standard when it comes to the ideal donor
is an HLA-identical sibling donor (Tiercy, 2016). However, only 30% of recipients are
transplanted with an HLA-identical sibling. If an HLA-identical sibling is not available, then
a matched unrelated donor is considered the gold standard. It is important to find an
appropriate match for a recipient in order to reduce the risk of graft failure, GVHD, and death
(Baxter-Lowe & Hurley, 2008). In order to find a suitable donor, two types of typing are
used: high-resolution typing and low-resolution typing (Tiercy, 2016). High-resolution
typing examines each locus at an allelic level, so it considers differences in alleles. Table 1
demonstrates high-resolution HLA typing which includes both the antigen and allele typed.
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For example, in Table 1, at antigen A, the recipient HLA high-resolution typing would be
“A*02:01”, and it includes the allele portion “01”. Low-resolution typing only examines it at
an antigen level. For example, it would be typed as “A*02”. For bone marrow and peripheral
blood-derived HSC products, high-resolution typing at all 10 loci is typically recommended,
and donors are considered suitable if they match at least 9 out of 10 loci (Demiriz,
Tekgunduz, & Altuntas, 2012). Table 1 demonstrates high-resolution typing of a donor and
recipient. They demonstrate allelic-matching at all loci except for the allelic mismatch at A2,
so the recipient and donor are considered a 9/10 match.
Table1. High Resolution Matching

A
02:01
11:01

Recipient HLA Typing
B
C

DRB1

DQB1

07:06

04:02

03:02

04:01

07:06

07:02

13:01

06:01

Donor HLA Typing
Match
Grade

A

B

C

DRB1

DQB1

02:01

07:06

04:02

03:02

04:01

11:02

07:06

07:02

13:01

06:01

9/10

For cord blood products, a match of at least 4 out of 6 loci at antigen A, B, and DRB1 is
recommended. In addition, low-resolution matching is examined at antigen A and B and
high-resolution matching is examined at DRB1. Table 2 demonstrates how low-resolution
matching occurs at antigen A and B where A2 is considered a mismatched, and highresolution matching occurs at DRB1, where they match at an allelic level.
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Table 2. Cord Blood HLA Typing

Match Grade

Recipient HLA TYPING
A
B
02:XX
07:XX

DRB1
03:02

03:XX

07:XX

13:01

Donor HLA TYPING
A
B
03:XX
07:XX

DRB1
03:02

03:XX

13:01

5/6
07:XX

This demonstrates how there is more flexibility when it comes to HLA compatibility of a
cord blood product and is advantageous to use for transplantation.
GVHD is a complication that can occur after allogeneic transplantation, and
emphasizes the importance of HLA compatibility between the recipient and donor. It is an
immune-mediated response that occurs after transplantation when the donor’s immune cells
react with the recipient’s histocompatibility antigens and starts attacking the recipient’s
tissues from different organ systems, including but not limited to the skin, liver, and lungs
(Kim, Kim, & Cho, 2013). GVHD can be categorized as acute GVHD (aGVHD) or chronic
GVHD (cGVHD) (Schroder & DiPersio, 2011). Traditionally, the classification was based on
time of development with aGVHD occurring within 100 days of transplant, and cGVHD
occurring 100 days after transplant with symptoms sometimes not appearing 2-5 years after
transplant. However, there has been a shift in this definition, and clinical and histological
features in addition to time of development are considered for classification. Examples of
clinical manifestations of acute GVHD include skin involvement such as maculopapular rash
5

and gastrointestinal involvement such as diarrhea (Chao, 2019). Each organ that is affected
by aGVHD is staged according to the extent of involvement. aGVHD is staged according to
number of organs affected and the extent of involvement. Further details on how each organ
system is staged by the International Bone Marrow Transplant Registry is demonstrated in
Table 3.
Table 3. aGVHD Staging and Grade
Stage
0
1
2
3
4

Skin
No GVHD rash

Liver (bilirubin)
< 2 mg/dl

Maculopapular
rash< 25% BSA
Maculopapular rash
25 – 50% BSA
Maculopapular rash
> 50% BSA
Generalized
erythroderma plus
bullous formation

2–3 mg/dl

Gut (stool output/day)
< 500 ml/day or
persistent nausea.
500–999 ml/day

3.1–6 mg/dl

1000–1500 ml/day

6.1–15 mg/dl

Adult: >1500 ml/day

>15 mg/dl

Severe abdominal pain
with or without ileus

Stage 1–2
Stage 3 or
Stage 4 or

None
Stage 1 or
Stage 2–3 or
Stage 4

None
Stage 1
Stage 2–4
-

Grade
I
II
III
IV

The overall extent of aGVHD is assigned an overall grade based on simple calculations of
the individual staging scores (Jacobsohn & Vogelsang, 2007). Grade I-II aGVHD is typically
described as mild to moderate, while grade III-IV is typically described as severe to lifethreatening and thus considered high-grade aGVHD. Also, the overall aGVHD grade
demonstrates correlation with mortality with recipients experiencing grade III and grade IV
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having a 30% and 5% probability of achieving long-term survival, respectively (Cahn, et
al.,2005). In contrast, there is a >80% chance of long-term survival achievement with
recipients that experience a grade I-II aGVHD. There is a similar scoring system to stage
cGVHD that is based on the organs affected and extent of involvement. However, there is
only two categories to determine the overall grade of cGVHD: limited and extensive (Socié
& Ritz, 2014). cGVHD is categorized as limited if it only there is only skin and/or liver
involvement. If there is other organ involvement including eye, lungs, salivary glands, and/or
other organs, it is considered extensive cGVHD. In addition to the degree of HLA matching
between donor and recipients, other risk factors for GVHD development include HSC source,
the preparative regimen, age, differences in sex between donor and recipient, and donor
cytomegalovirus (CMV) serology among other risk factors (Bhutani, 2015). However, the
effect of CMV serostatus on transplant outcomes and risk of developing GVHD has not been
consistent across studies, and further research is needed to fully understand its effects
(MacMillan, et al., 2009).
Although an HLA matched donor decreases the risk of GVHD development, an
estimated 40% of recipients still develop aGVHD despite receiving HLA identical products
(Ferrara, Levine, Reddy, & Holler, 2009). High-grade aGVHD occurs in approximately 1118% of allogeneic transplant recipients, and the mortality rate ranges from 70-90% for the
severest grade of aGVHD (Henig & Zuckerman, 2014). According to data submitted to the
Center for International Blood and Marrow Transplant Research (CIBMTR), from 20152016, one of the main causes of transplant-related mortality is GVHD (D’Souza & Fretham,
2018). GVHD was the cause of death for 8% of recipients that died within 100 days after
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transplant and 10% for recipients that died after the 100 days mark. Overall UCB transplant
recipients experience lower rates of GVHD. According to a study by Herr et al., the results
showed that the rates of aGVHD were approximately 12% and cGVHD were approximately
10% when examining cord blood transplants that occurred within the European Union
(2010). These rates emphasize the importance of further research to understand the
development of GVHD to minimize risks for future transplantation.
After identifying and confirming a donor, the HSC must be extracted from the donor.
The process of extraction differs depending on the HSC source, which includes bone
marrow, peripheral blood, and umbilical cord blood. For HSC extraction from a bone marrow
source, the donor is under either local or general anesthesia (Khaddour & Mewawalla, 2019).
The process involves inserting a hollow needle into the bone, typically the anterior or
posterior iliac crest, to collect the bone marrow. Multiple aspirations are completed with the
total depending on how many cells need to be collected, usually 1 to 1.5 liters with 15 mL
per aspiration. For HSC extraction from peripheral blood source, the donor must take a
mobilization agent, such as granulocyte colony-stimulating factors (G-CSF), prior to
collection (Hatzimichael & Tuthill, 2010). The mobilization agent helps increase the number
of HSC in the peripheral blood of the patient which is then collected through apheresis.
Finally, HSC extraction from umbilical cord blood source takes place after birth (Risso et al.,
2018). A needle is inserted into the cord and at least 40 milliliters of blood is collected. The
blood is then cryogenically frozen and stored at a cord blood bank.
There are different factors that are considered when choosing among these three
sources. When comparing these three sources, there are differences in risk and recovery
8

(Demiriz, Tekgunduz, & Altuntas, 2012). There are many factors that differentiate UCBderived HSC products from bone marrow and peripheral blood-derived HSC products. UCB
is the only source where there is no risk for the donor during the extraction process, and there
is a much shorter duration of time needed to find a donor, about one month or less. Both
peripheral blood and bone marrow extraction poses as a risk to the donor, and it typically
takes 3 to 6 months to find a suitable donor. Recipients that receive HSC from a peripheral
blood source are also at a higher risk of GVHD (Bensinger, 2012). This pattern is most likely
due to the fact that there is typically a higher number of T-cells found in peripheral blood
grafts compared to bone marrow grafts, thus recipients are more likely to develop an
immunological response to their transplant if they received peripheral blood derived products
than bone marrow derived products (Gorin et al., 2002). As previously mentioned, recipients
that received a UCB-sourced product typically experience lower rates of GVHD and most
likely this is contributed to the fact that there are lower counts of total T-cells with the
majority being naïve T-cells found in UCB-sourced products compared to peripheral blood
and bone marrow (Politikos & Boussiotis, 2014). One major limitation to UCB-derived HSC
products is that transplantation using these cells is typically limited to pediatric patients. The
amount of HSC needed for transplantation is determined by the recipient’s weight and ranges
from 2 to 4 x 108 nucleated cells per kilogram of the recipient’s weight (Karanes et al.,
2003). There are typically not enough cells within a single UCB unit to use for
transplantation in adults unless multiple UCB units are used. Another disadvantage is that
UCB recipients take a longer time to achieve engraftment compared to peripheral blood and
bone marrow recipients with peripheral blood recipients having the fastest recovery time
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(Demiriz, Tekgunduz, & Altuntas, 2012). Cord blood units contain fewer HSC than other
sources, and the more limited number of HSC most likely contributes to the slower
engraftment time. Also, due to this delay in engraftment there is a higher risk of posttransplant infection with UCB than bone marrow or peripheral blood (Galgano & Hutt,
2017). As previously mentioned, after conditioning and infusion, recipients undergo a
neutropenic phase where they are more immunocompromised, thus more susceptible to
infections. Since cord blood recipients typically take a longer time to achieve engraftment,
this means that they are also in this neutropenic phase longer and have an increased risk of
infections. Although UCB transplants are associated with longer engraftment times, UCB
transplants are also associated with high rates of engraftment at 85-100% of transplants
achieving engraftment (Danby & Rocha, 2014).
As previously mentioned, UCB transplantation is an advantageous option for
individuals especially those with no feasible matched donor options due to more rapid
availability, lower rates of GVHD, and minimal extraction risk among other factors. As of
2017, approximately 700,000 UCB units have been donated and 40,000 UCB
transplantations have occurred (Ballen, 2017). According to data published by CIBMTR,
from 2013-2017, CBU transplants account for 4% (n = 4,335) of all transplants that were
performed in the United States and reported to CIBMTR (D’Souza & Fretham, 2018). For
comparison, peripheral blood transplants account for 86% (n = 91,636) and bone marrow
transplants account for 9% (n = 9,833).
The importance investing in cord blood research, especially to better understand
advantages to using it over other HSC sources, is reflected in the global burden of cancer
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especially pediatric cancer as it continues to increase with about 200,000 children and
adolescent diagnosed annually (Rodriguez-Galindo et al., 2013). Although there have been
improvements in the diagnosis, treatment, and outcome of pediatric cancers in high-income
countries (HIC), which is reflected in the over 80% 5-year survival rate, low to middleincome countries (LMIC) continue to face low rates of survival with survival rates varying
across regions (Force et al., 2019). For example, it is estimated that the pediatric cancer
mortality rate is about 90% in Sub-Saharan Africa. This is especially concerning because
more than 80% of the pediatric population at risk for developing cancer are in LMIC
(Rodriguez-Galindo et al, 2013). The availability and accessibility of treatment is especially
important due to this continued upward pattern of the global burden of pediatric cancer.
Although ideally a matched donor source is used for transplantation and there are over 33
million marrow donors registered globally, only about one third of patients are able to find an
HLA-matched unrelated donor (Brunstein & Weisdorf, 2009). The success rate of finding a
donor varies across racial and ethnic backgrounds with recipients of racially and ethnically
diverse backgrounds having a much lower success rate than Caucasian recipients. Further
support of UCB banking through education, resources, and research provides more options
for alternative sources especially since UCB is rapidly available and mismatched-HLA UCB
products still demonstrate high rates of engraftment and low incidences of graft-versus-host
disease.
In addition to potentially addressing the needs of patients facing malignant diseases
such as hematological cancers, HSC transplantation also serves as the only cure for otherwise
debilitating or deadly non-malignant diseases. Sickle cell disease (SCD) is an example of an
11

inherited non-malignant hematological disease where currently the only cure is HSC
transplantation (Bernaudin et al., 2007). SCD affects millions of people globally especially in
malarial endemic areas (Wastnedge et al., 2018). The higher prevalence in these areas are
due to the fact that individuals that are genetically heterozygotic for SCD are protected
against malaria (Luzzatto, 2012). These areas are also resource poor areas with limited access
to healthcare which often translates to poor disease outcomes and survival rates for SCD. In
LMIC, which accounts for 90% of SCD, it is estimated that 500 children die every day due to
lack of proper care and 90% of children inflicted with SCD do not reach their fifth birthday
(Wastnedge et al., 2018). These poor survival rates demonstrate the importance of investing
resources and funding research to help create better outcomes for individuals affected by
SCD especially in the area of cord blood transplantation. As previously mentioned, HSC
transplantation serves as the only curative option and with the advantages of CBU over other
HSC sources and a large pediatric population, CBU serves as a viable option to help combat
the high global burden of disease and low survival rates.
In addition, expansion of the cord blood registry has the potential to address ethical
concerns regarding the use of donors, both children and adults, to recover hematopoietic stem
cells. The current process of UCB collection does not cause harm to the mother or the baby
or increase their risk of adverse events (Cavusoglu et al., 2017). Other sources of HSC
including bone marrow and peripheral blood must be recovered directly from patients, so
there are risks of injury, adverse events, and even death. The risks are extremely rare, but
there is still a chance of causing adverse effects in a donor that was completely healthy prior
to donation. In a study by Halter et al., 383 transplant teams were given a survey to complete
12

regarding transplantation outcomes (2009). The study found that out of a total of 51,024
transplantations, 37 reported severe adverse events, five donors had died, and 20 reported
hematological malignancies. As the results demonstrate, the risks are very rare and could be
considered statistically negligible, but there is an ethical conflict of placing an otherwise
healthy individual in a situation that could be potentially harmful or fatal. Another area that is
potentially ethically concerning is the use of children as donors, including both using
preimplantation HLA typing to create a donor child or using a matched-sibling as a donor
(Devolder, 2005). The idea of having a child solely to serve as a donor for a sibling can be a
potential gray area as some people see it as creating a child to basically use their parts. Using
children in general can be a potential concern because the children are typically not the ones
making the decision to continue with the donation process. They do not have full autonomy
in regards to donation. Using a UCB product eliminates these ethical concerns.
Public Health Significance
In 1957, the first allogeneic bone marrow transplantation was performed in New
York, and involved using the identical twin of the recipient as the donor (Henig &
Zuckerman, 2014). Since that successful event, the field has rapidly evolved through research
and development to where allogeneic transplants no longer just involve matched siblings but
also include the options of matched and mismatched unrelated donors, and umbilical cord
blood (UCB) units as a donor source. The field continues to evolve and now even includes
haploidentical donors. The use of haploidentical donors is an alternative option if a matched
sibling donor is not available and involves using a donor that is half-matched typically the
mother or father of the recipient (Zheng et al., 2020). The availability of new sources of
13

hematopoietic stem cell (HSC) donations means that transplantation is a more accessible
treatment for individuals affected by cancer and other life-threatening disorders.
In the United States, cancer is currently the second leading cause of death overall
among all ages (21.3% of total deaths), the third leading cause of death in children between 1
to 4 years of age and 10 to 14 years of age (8.4% and 13.6% of total deaths in respective age
groups), and the second leading cause of death in children between 5 to 9 years of age
(17.8% of total deaths within age group) (Heron, 2019). Hematological cancers are the most
common type of cancer among children with the most common being pediatric leukemia,
which represents about 30% of pediatric cancers (Madhusoodhan, 2016). Since HSC
transplantation is an established treatment for high-risk and relapsed cancer patients, the
overall rates of pediatric cancer emphasize the importance of the expansion and use of UCB
units as products. UCB transplantation is typically reserved for the treatment of pediatric
patients due to the limitations in cell numbers per UCB unit (Brunstein & Weisdorf, 2009).
Adult patients undergoing UCB transplantation have to use two or more units of UCB in
order for the number of cells to be sufficient. The expansion of the UCB registry through
increased cord blood banking is especially important in the context of global cancer rates,
which as previously mentioned, continues to rise.
Even though preventative care is the focus of public health and transplantation is a
form of treatment for curative purposes, it has important implications in the field of public
health. Most of the individuals that are eligible for transplantation are inflicted with diseases
that have a genetic component, such as some hematological cancers, sickle cell disease, and
severe combined immunodeficiency, and often there are no preventative measures that affect
14

the development of disease, and transplantation is the only option that provides them with a
better quality of life or a better chance of survival. Also, from a global perspective, diseases
such as hematological cancers and SCD are concentrated within specific communities, which
are often resource-poor with limited access to healthcare. This demonstrates that there needs
to be more outreach in terms of educational programs, policy development, resource
distribution, and projects that focus on understanding the population. In addition to making
transplantation a more accessible treatment option for these populations, it is also important
to understand their issues and needs to help develop outreach programs and provide
resources that would improve the health of the community overall.
Although UCB units offer many advantages including more potential product sources
due to less stringent HLA-matching criteria, products more rapidly available, and addresses
ethical issues concerning use of donors among others, the past few years demonstrate that
there is a decrease in the overall use of UCB units (Rafii et al., 2016). Alternative sources of
products, such as HSC from haploidentical donors, could be most likely contributing to this
current trend of moving away from UCB transplantation. However, due to continued high
rates of cancer both within the United States and globally especially among pediatric
patients, it is important to continue investing in UCB-related treatments through research,
development, and educational outreach programs relating to banking. This includes further
research into understanding the advantages of using UCB source products including lower
rates of GVHD and consistent levels of engraftment achievement to help encourage its use as
a viable option. As GVHD is one of main causes of transplant-related mortality, it is
important continue research in GVHD outcomes from using UCB source products in order to
15

better understand how to decrease transplant-related complications and improve survival
rates.
Hypothesis and Study Objectives
The purpose of this study is to determine the difference in incidence of GVHD among
pediatric cord blood transplant recipients based on human leukocyte antigen match grade.
Current literature supports that unlike other stem cell products, such as peripheral blood and
bone marrow, recipients do not need to be matched strictly according to high-resolution HLA
requirements for cord blood transplantation in order to achieve engraftment for a successful
treatment. Also, there are limited studies on how primary disease affects cord blood
engraftment and GVHD, so this study will help further understand this gap in knowledge.
The purpose of the study can be further summarized through the following objectives:


Primary Objective:
o To determine how HLA match grade compatibility of CBU transplantation
affects GVHD development and engraftment achievement status specifically
if an HLA mismatched product increases the risk of GVHD development or
engraftment failure



Secondary Objectives:
o To analyze how primary disease of transplantation recipient affects GVHD
development and engraftment achievement status
o To analyze how CBU origin affects GVHD development and engraftment
achievement status

16

Based on current literature, I hypothesize that there is no increased risk of failure to
achieve engraftment and GVHD occurrence among mismatched UCB recipients and that
primary disease has no effect on either engraftment or GVHD development.
METHODS
Study Design
A retrospective cohort study was conducted to study engraftment achievement and
the incidence of GVHD among cord blood transplant recipients based on HLA compatibility
and match grade.
Study Subjects and Study Setting
The study involved pediatric patients that underwent transplantation at the Bone
Marrow Transplant (BMT) unit at Texas Children’s Hospital (TCH) at the Texas Medical
Center in Houston, Texas. Subjects were eligible for selection based on the following
criteria:
Inclusion Criteria:
Subjects will be considered eligible for the study based on the following inclusion
criteria: 1) The patient must have undergone transplantation at the BMT unit at TCH, 2)
Patients must have received a cord blood product and only received product from one donor,
or in other words, they only received one CBU, and 3) They must be a pediatric patient and
under the age of 18, and 4) The patient must have underwent cord blood transplantation
between 2008 and June 2019.
Exclusion Criteria:
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Subjects will not be considered eligible for the study based on the following
exclusion criteria: 1) If they received multiple CBU or received mixed products, e.g. bone
marrow product in addition to cord blood, 2) If they underwent transplantation at an outside
hospital and is currently being followed by TCH, 3) If they are 18 years of age or older, and
4) if they underwent transplantation after June 2019, since not enough time has passed for
these patients to be examined for engraftment and graft-versus-host disease.
Sample Size Calculation and/or Study Power
A sample size of 240 is required for 80% power was calculated based on the
following assumptions:


α = 0.05



Incidence of GVHD among matched and mismatched is 9% and 22%, respectively

Data Collection and Data Analysis
The BMT unit at TCH is part of the network of CIBMTR under the National Marrow
Donor Program, which requires the unit to submit data relating to patient history, details of
transplant, and outcome to CIBMTR. In addition, the BMT unit has an in-house database,
StemSoft, which can be used to generate data sets for analysis based on what is reported to
CIBMTR. Information regarding patient demographics, transplant history, product type
(matched or mismatched), conditioning, engraftment status, acute GVHD, and chronic
GVHD was obtained from StemSoft. The classification of acute GVHD and chronic GVHD
at TCH is according to the traditional criteria that focuses on the time of development with
GVHD occurring within 100 days of transplant considered acute GVHD, and GVHD
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occurring 100 days after transplant considered chronic GVHD (Schroder & DiPersio, 2011).
Information regarding HLA typing, product country of origin, donor’s maternal CMV status,
and HLA match grade are not reported in the database so this information was manually
ascertained through medical records and HLA reports. The information that was manually
ascertained was also verified by Dr. Caridad Martinez, the assistant Director of the BMT unit
at TCH, to ensure accuracy.
In order to protect patient confidentiality and ensure data security, all data that
contains patient information will be compiled at the Feigin Tower at TCH. The building is
limited to TCH and Baylor College of Medicine employees, and the work areas in the
building are only accessible by badge by authorized individuals. All medical records that will
be used in this study are electronic, so there are no risks of misplacement of physical copies.
All computers at TCH are password protected and only limited to authorized users. In
addition, the data prior to de-identification will be locally stored on a computer in office 1540
at the Feigin Tower that only the researcher can access. The office can be locked and is
located in an area that is only accessible by badge specific individuals. Once the data is
compiled, it will be de-identified for analysis.
The statistical analysis software STATA will be used for data analysis. Data analysis
will include calculation of relative risk to determine the risk of occurrence of GVHD or
engraftment failure after exposure to risk factors such as match grade, primary disease type,
geographical origin of CBU, and donor’s maternal CMV status. For all statistical analysis, a
p-value of less than or equal to 0.05 will be used to determine significance. Additional tests
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of statistical analysis will include Chi-Square tests to determine associations between matchgrade and acute GVHD development.
Human Subjects
During the data collection stage of the study, sensitive health information was
accessed through the StemSoft database and electronic medical records in order to create data
sets for analysis. There was no direct patient contact for this study. The handling of sensitive
health information was completed following BMT departmental protocols. In addition, Dr.
Caridad Martinez has provided a letter for her permission of use of data for the study on
January 8, 2020. The data will be de-identified for analysis, and, as previously mentioned,
only the primary investigator and Dr. Martinez will have access to the data prior to deidentification solely for data collection purposes. Furthermore, the study was approved by the
IRB under HSC-SPH-20-0023 on January 28, 2020. IRB approval was obtained to ensure
that the study adheres to strict research guidelines
RESULTS
Overall Transplant Recipient Characteristics
A total of 102 cord blood transplantations occurred at TCH between 2008 and June
2019. After the recipients’ eligibility status was determined based on the previously
mentioned inclusion and exclusion criteria, a total of 82 recipients were included for analysis.
A summary of the transplant recipient characteristics is shown in Table 4. The median age of
the recipient at transplant was 0.90 years (10.8 months) with the youngest recipient aged 0.13
years old (1.6 months) and the oldest aged 9.31 years old. As of the time of data collection,
74.39% (n=61) of recipients were alive and 25.61% (n=21) of recipients had died. Figure 1
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details the cause of death of the recipients in this cohort. There was a total of 21 recipients
(25.61%) that died, and their cause of death includes the following: 47.62% (n=10) from
Relapse/progression/persistent disease, 9.52% (n=2) from GVHD, 9.52% (n=2) from
transplant-related infections, 4.762% (n=1) from other transplant-related causes, and 28.57%
(n=6) from other causes. Approximately 59.76% (n=49) of recipients underwent
transplantation due to a non-malignant primary disease including anemia/hemoglobinopathy
(n=4), histiocytic disorder (n=2), immune deficiency (n=37), inherited disorder of
metabolism (n=4), and other non-malignant diseases (n=2). Approximately 40.24% (n=33) of
recipients underwent transplantation for malignant diseases including acute leukemia (n=28)
and MDS (n=5).
Overall Cord Blood Unit Characteristics
A summary of the cord blood unit characteristics is included in Table 5. The median
number of years between the date of UCB collection and date of transplantation is 3.67 years
(range 0.52-19.49 years). Approximately 81.71% (n=67) of CBU were from a domestic
origin, meaning that they were collected and stored at a cord blood bank within the United
States. In addition, 18.29% (n=15) of CBU were from an international origin thus collected
and stored at a cord blood bank outside the United States. Further examination of the donor
sex determined that 50.62% (n=41) were female and 40.38% (n=40) were male. Finally, the
maternal CMV status of the CBU were as followed: 29.27% (n=24) negative, 47.56% (n=39)
positive, and 23.17% (n=19) unknown.
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Effect of HLA Compatibility on the Development of acute GVHD and Engraftment
Table 4 shows how the 82 recipients are categorized according to both the less
stringent cord blood method of matching across 6 loci and the high-resolution HLA matching
across 10 loci. When examining how the recipients are grouped based on HLA matching out
of 6, 1.22% (n=1) recipients had an HLA-match grade of 4/6 to the donor, 59.76% (n=49)
were a 5/6 match, and 39.02% (n=32) were a 6/6 match. When examining how the recipients
are grouped based on HLA matching out of 10, 21.95% (n=18) matched 10/10, 19.51%
(n=16) matched 9/10, 41.46% (n=34) matched 8/10 or 7/10, 12.20% (n=10) matched 6/10 or
5/10, and 4.88% (n=4) matched 4/10 or 3/10.
A Chi-Square analysis was performed in order to determine the association between
the 6 loci or 10 loci match grade and development of acute GVHD. The results for the 6 loci
match-grade (Χ2 = 0.66; p=0.96; Table 6) and 10 loci match-grade (Χ2 = 4.85; p=0.99; Table
6) were both found to be not significant indicating that there was no association between the
match grade and aGVHD development for each criterion. In addition, one important
assumption of the Chi-Square analysis test is that the expected value of each cell is greater
than 5. Since multiple cells during the analysis for both 6 and 10 loci match-grade does not
meet this criteria, a Fisher’s exact test was performed. However, the p-values for both factors
for the Fisher’s Exact test was greater than 0.05 thus not significant.
Examination of the aGVHD rates show that 90.12% (n=73) did not experience
GVHD while 4.94% (n=4) experienced a Grade I-II of aGVHD and 4.94% (n=4) experienced
a Grade III-IV of aGVHD. For cGVHD, 98.55% (n=68) experienced no cGVHD while
1.45% (n=1) experienced extensive cGVHD. Please note that the total number of recipients
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that were examined for acute and chronic GVHD development do not add up to 82 recipients.
This is due to the recipients passing away before they can be assessed for development of
GVHD. Further analysis of the data was completed to determine if mismatched HLA based
on both 6 loci and 10 loci criteria is a risk factor for aGVHD development. The results
support that there is no significant increased risk of aGVHD development for recipients with
mismatched donors (RR 1.09; 95% CI, 0.28-4.24; p= 0.61; Table 7) when analyzed
according to the 6 loci criteria. In addition, there was no significant increased risk of aGVHD
development among recipients with mismatched donors versus matched donors (RR 0.86;
95% CI, 0.199-3.89; p= 0.57; Table 7) when analyzed according to the 10 loci criteria.
In addition, 96.34% (n=79) of transplant recipients achieved engraftment while
3.66% (n=3) did not achieve engraftment. The data was analyzed to determine if mismatched
HLA is a risk factor for engraftment achievement failure. Based on analysis of the
relationship between HLA compatibility and engraftment achievement as shown in Table 8,
there is no significant increased risk of not achieving engraftment among recipients with
mismatched donors versus matched donors (RR 1.28; 95% CI, 0.12-13.54; p = 0.66) when
analyzed according to the 6 loci criteria. The results for the 10 loci criteria also did not
demonstrate a significant increase of risk of not achieving engraftment among recipients with
mismatched donors (RR 0.56; 95% CI, 0.05-5.86; p= 0.53; Table 8).
Effect of Primary Disease on the Development of acute GVHD and Engraftment
As previously stated, 59.76% (n=49) of recipients underwent transplantation due to a
non-malignant primary disease, and 40.24% (n=33) of recipients underwent transplantation
for malignant diseases. The data was further analyzed to determine primary malignant
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diseases were a risk factor for developing aGVHD. Further analysis to understand the
relationship between primary disease and development of aGVHD show that recipients with
primary malignant diseases had 2.55 times (95% CI, 0.66-9.95; p=0.154; Table 7) the risk of
developing aGVHD than recipients with primary non-malignant diseases, however the results
are not significant. Since the 95% confidence interval contains the null value of 1, the results
are not significant. When examining the relationship between primary disease and
engraftment achievement, it was calculated that recipients with primary malignant diseases
had 0.742 times (95% CI, 0.07-7.86; p=0.65; Table 8) the risk of not achieving engraftment
than recipients with primary non-malignant diseases, so primary malignant disease can be
interpreted as a protective factor for achieving engraftment. However, the difference in risk
was found to be not significant for the same reason as previously mentioned.
Effect of CBU properties on the Development of acute GVHD and Engraftment
Since there are limited studies on the effect of geographic origin on CBU and
development of GVHD, the data was analyzed to determine if a CBU of international origin
had a higher risk ratio of developing GVHD than those of domestic origin. Further analysis
to examine the association between geographical origin of CBU collection and development
of GVHD showed that recipients transplanted with a CBU from an international origin had
0.628 times the risk (95% CI, 0.08-4.73; p=0.54; Table 7) of development of aGVHD than
recipients transplanted with a CBU from a domestic origin. However, since the 95%
confidence interval contains the null value of 1, the results are not significant, and there is no
significant increase in risk for recipients that was transplanted with a CBU from a
international origin. Finally, CMV serology status is not a well understood risk factor of
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GVHD, so the data was analyzed to determine if a positive donor’s maternal CMV status was
associated with an increased risk of GVHD development in the recipient. Furthermore, when
examining the association between GVHD and donor’s maternal CMV status, it was found
that recipients that were transplanted with a CBU unit whose donor’s maternal CMV status
was positive had 0.821 times the risk (95% CI, 0.20-3.35; p=0.54; Table 7) of developing
aGVHD than recipients that were transplanted with a CBU unit whose donor’s maternal
CMV status was negative, which can be interpreted as a positive CMV status being a
protective factor against the development of aGVHD. However, the risk was found to be not
significant based on the p-value (0.54) and the 95% CI containing the value of 1.
Effect of Recipient Sex and Mismatched Recipient-Donor Sex on Development of acute
GVHD
Based on the discrepancy between the number of male (n=55) and female recipients
(n=26) that underwent UCB transplantation, further analysis was completed to determine if
the sex of the recipient was a potential risk factor for development of aGVHD. It was
examined if males had an increased risk of aGVHD development. Based on further analysis,
it was found that male recipients had 3.31 times the risk (95% CI, 0.43-25.52; p=0.20; Table
7) of developing aGVHD than female recipients. However, the risk was found to not be
significant due to the Fisher’s exact test p-value of 0.20 and due to the CI including 1.
In addition, it was also examined if differences in sex between the recipient and donor
is a risk factor for aGVHD development. Further analysis conducted to determine if a
mismatched recipient-donor sex was associated with an increased risk of aGVHD. Based on
the results of the analysis, it was found that mismatched recipient-donor sex pairs had 0.59
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times the risk (95% CI, 0.15-2.29; p=0.34; Table 7) of developing aGVHD than matched
recipient-donor sex pairs which indicates it is a protective factor. This result was also found
to not significant due to the p-value (0.34) and the CI containing 1.
DISCUSSION
Analysis of whether HLA match grade, primary disease, geographical origin of CBU,
and donor’s maternal CMV status as potential risk factors for GVHD development were
shown to be not significant. In addition, analysis of HLA match grade and primary disease as
potential risk factors of failure to achieve engraftment were also not significant. The purpose
of this study was to analyze these risk factors to see if there is an overall consistency with
previous studies to further support that transplantation with CBU provides advantages over
other sources of HSC that would be especially beneficial to pediatric patient populations.
Overall, the results of this study were consistent with the following previous studies.
About 10% of the recipients in this cohort developed aGVHD which is similar to previous
studies that estimated around 12% of recipients develop aGVHD (Herr et al., 2010).
However, the percentage of recipients that developed cGVHD for this cohort was about 1%
while it was estimated to be around 10% by Herr et al. (2010). Many factors could have
contributed to this discrepancy including a larger sample size for other studies, discrepancy
in GVHD treatment protocols at TCH versus other institutions, and differences in the makeup
of the population included in the study especially if other studies included a mix population
of pediatric and adult recipients. For example, in terms of differences in population make-up
as a potential factor, this study only included pediatric patients, and age is considered a
potential risk factor for GVHD development as older recipients being at increased risk
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(Bhutani, 2015). Furthermore, the severity of disease for recipients could have had an effect
on the rates of GVHD. About 26% of recipients died after undergoing transplantation with
about 10% of the total deaths due to GVHD complications. This is consistent with the data
reported to CIBMTR that estimates 8-10% of recipients died as a result of GVHD
complications (D’Souza & Fretham, 2018). Even though the findings for mismatched donorrecipient sex were not significant, the results contradicted previous studies since it was found
to be a protective factor while previous studies found it to be a risk factor (Bhutani, 2015).
Further research is necessary to get a comprehensive understanding of how the factor affects
GVHD development. Although the intention of the study was to also analyze the risk of
developing cGVHD, further analysis could not be completed due to only one recipient
developing cGVHD. Analysis of the current data would not have reflected accurate findings
due to the rarity of the condition. Overall, as previously discussed, this study demonstrates
the consistency across studies regarding the rates of developing GVHD which further
supports the benefits of CBU transplantation.
The primary objective of the study was to determine how HLA match grade
compatibility of CBU transplantation affects GVHD development and engraftment
achievement status. Based on statistical analysis of the data collected, there was no
significant association between match-grade (both for 6 loci and 10 loci) and development of
aGVHD as well as no statistically significant increased risk of aGVHD development among
mismatched versus matched recipients. Analysis of engraftment status showed similar results
in that there was no significant difference in risk between mismatched versus matched
recipients in failing to achieve engraftment. This further supports that there is flexibility in
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terms of HLA matching in CBU without the risk of developing adverse reactions relating to
GVHD and engraftment failure. Furthermore, about 96% of recipients achieved engraftment
which is on par with previous studies that consistently showed high engraftment rates among
CBU transplant recipients where 85-100% of recipients achieved engraftment (Danby &
Rocha, 2014). Although age has been shown to be a risk factor for development of acute
GVHD, studies have consistently supported that children are 12 years old or younger at very
low risk for both aGVHD and cGHVD (Qayed et al, 2018). Further analysis on age as a risk
factor was not completed since the oldest recipient in this cohort is approximately 9 years old
and younger than threshold for age to be considered a risk factor.
The secondary objectives focused on other potential risk factors that could contribute
to GVHD development and engraftment failure. The type of primary disease was not found
to be a significant risk factor in the development of aGVHD or engraftment failure. Also, the
geographical origin of the CBU and donor’s maternal CMV status were not found to be
significant risk factors in the development of aGVHD. There are limited prior research
studies that examined the type of primary disease and geographical origin of CBU as
potential risk factors. A positive donor’s maternal CMV status is cited as a risk factor across
some studies, however, this study found no significant increase in the risk between positive
versus negative donor’s maternal CMV status and development of aGVHD. Nonetheless, one
important factor that could have contributed to this outcome is the small sample size when
examining CMV status. Due to limitations in data collection, the donor’s maternal CMV
status for recipients that were transplanted in the earlier years is unknown. The study
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included 82 recipients but the CMV status could not be collected for 19 recipients which
could have greatly affected the outcome of the analysis.
Further research studies are recommended to gain a more comprehensive
understanding of CBU transplantation. A comparison of these risk factors among bone
marrow and peripheral blood transplant recipients in addition to CBU recipients would be
able to provide more context for the results of analysis. In addition, severity of disease is also
an important factor that could affect engraftment and GVHD development, however, due to
limitations in data collection regarding this factor, further analysis could not be completed.
This would be an important risk factor and potential confounding factor for this study that
should be assessed in future studies.
There are notable limitations that should be considered for this study. As like most
retrospective cohort studies, the data used for analysis was originally collected for other
purposes so not all relevant risk factors and variables for the study objectives were
necessarily collected. The data sets that were generated through the StemSoft database were
mostly demographical information relating to the recipient and transplant. For example, for
information relating to GVHD, it only includes the grade of GVHD but not the organs that
were affected and their individual staging. Additional details relating to different aspects of
transplantation would have allowed for a more comprehensive analysis of the data that would
have provided more context for the study findings. Also, information relating to GVHD
cannot be as easily manually ascertained through clinical notes, since the GVHD status is
based on the discretion of the treating physician and not necessarily based on pathology or
lab reports. This could also lead to inconsistency of interpretation of GVHD status across
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physicians, however it is unlikely since there are specific requirements for each stage, grade,
and type of GVHD that helps minimize discrepancies. Nonetheless, it would be beneficial to
collect more comprehensive data for the database for future studies.
Another limitation for this study is that GVHD status was reported according to the
traditional criteria that focused more on time of diagnosis rather than histological features. As
the traditional criteria becomes more obsolete across different hospitals and clinics, and the
new criteria becomes more prevalent, the findings of this study might not necessarily be as
relevant, and further studies that examines the new criteria would be necessary.
In addition, another notable limitation is that there is no real time quality control for
the data that is entered into the StemSoft database. The data itself especially data relating to
GVHD is separately verified by primary physicians, however, there is no system in place to
verify the data that is actually entered accurately into the database thus leaving room for
human error especially typographical errors.
Finally, the small sample size contributed to the low-power of the study. 240
participants were required to achieve 80% power, however, the sample size of 82 fell short of
this requirement. Despite the results demonstrating that specific potential risk factors do not
increase the risk of aGVHD development and failure to achieve engraftment, the analysis is
inconclusive due to the small sample size not providing the power necessary to determine
accurate significance. The sample size could have potentially affected the results of the study
including contributing to the non-significant findings. A smaller power would mean that the
probability of a type II error increases, which potentially contributes to the non-significant
findings in a study. Also, a larger sample size would have been more ideal in terms of
30

analyzing cGVHD development. Only one recipient developed cGVHD in this cohort, and
in-depth analysis of cGVHD risk factors based on solely one patient could be misleading and
not provide accurate results.
Despite limitations, the study further supported the advantages of CBU
transplantation in terms of low-rates of GVHD development regardless of HLA match grade
and high rates engraftment achievement. In addition, since there are currently limited studies
on how match grade, primary disease, CBU geographical origin, and donor’s maternal CMV
status affects transplantation outcomes, the study provides a basic understanding that future,
large-scale studies can further examine. It will be an important stepping stone to help
advance future studies to help better understand CBU transplantation to further encourage its
use especially in pediatric populations.
CONCLUSION
Previous research studies have shown that the use of CBU for transplantation
provides advantages over other sources of HSC including less stringent HLA matching
criteria, no risk to donor, lower rates of GVHD, and higher rates of engraftment among other
factors (Demiriz, Tekgunduz, & Altuntas, 2012). The results of the study further support that
UCB-sourced products offer flexibility in HLA matching criteria and mismatched recipients
were not associated with an increased risk of developing GVHD or failure to achieve
engraftment. In addition, the type of primary disease, geographical origin of CBU, and CMV
status did not increase the risk of developing GVHD or failure to achieve engraftment.
However, as previously mentioned, further studies large-scale studies would provide more
conclusive results due to achieving the power necessary to determine significance in
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findings. As this study further supports the benefits of CBU transplantation, it emphasizes the
importance of further research and investment into cord blood banking and transplantation.
Further research is important to allow for a more comprehensive understanding of CBU
transplantation. Due to limitations of CBU transplantation, the pediatric population would
benefit the most from continued support and research. This is especially important because
pediatric cancer rates continue to rise globally and transplantation offers the only curative
option for many genetic diseases thus CBU transplantation serves as a viable option that
could help combat the increased rates of disease.
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Table 4. Transplantation Characteristics Summary
Factors
Recipient age at transplant (years), median (range)
Recipient Sex, n (%)
Female
Male
Survival Status, n (%)
Alive
Dead
Primary Disease, n (%)
Acute leukemia
Anemia/hemoglobinopathy
Histiocytic disorder
Immune deficiency
Inherited disorder of metabolism
MDS
Other non-malignant diseases
Primary Disease Type, n (%)
Malignant
Non-Malignant
Acute GVHD, n (%)
None
Grade I-II
Grade III-IV
Chronic GVHD, n (%)
None
Limited
Extensive
HLA Compatibility, n (%)
Matching out of 6 Criteria
4/6
5/6
6/6
Matching out of 10 Criteria
3/10 or 4/10
5/10 or 6/10
7/10 or 8/10
9/10
10/10
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n = 82
0.90 (0.13-9.31)
27 (32.93)
55 (67.07)
61 (74.39)
21 (25.61)
28 (34.15)
4 (4.88)
2 (2.44)
37 (45.12)
4 (4.88)
5 (6.10)
2 (2.44)
33 (40.24)
49 (59.76)
73 (90.12)
4 (4.94)
4 (4.94)
68 (98.55)
0 (0)
1 (1.45)

1 (1.22)
49 (59.76)
32 (39.02)
4 (4.88)
10 (12.20)
34 (41.46)
16 (19.51)
18 (21.95)

Table 5. Cord Blood Unit Characteristics Summary
Factors
Time between collection date and transplant date (years),
median (range)
CBU origin, n (%)
Domestic
International
Donor CMV status, n (%)
Negative
Positive
Unknown
Donor sex, n (%)
Female
Male
Days to achieve engraftment, median (range)
Engraftment Achievement, n (%)
Yes
No
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n = 82
3.67 (0.52-19.49)

67 (81.71)
15 (18.29)
24 (29.27)
39 (47.56)
19 (23.17)
41 (50.62)
40 (49.38)
18 (8-44)
79 (96.34)
3 (3.66)

Table 6. Chi-Square Analysis for HLA Match Grade and aGVHD Development

Factors
6 Loci
Match
Grade
4/6
5/6
6/6
Total
10 Loci
Match
Grade
3/10
4/10
5/10
6/10
7/10
8/10
9/10
10/10
Total

aGVHD
Grade 0
(N=73)

1
43
29
73

1
3
1
6
12
19
15
16
73

aGVHD
Grades III
(N=4)

0
2
2
4

0
0
0
1
1
0
1
1
4

aGVHD
Grades IIIIV
(N=4)

0
3
1
4

0
0
0
1
1
1
0
1
4
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Total
(N=81)

Fisher’s
Exact

Χ2

P

0.66

0.96

1.00

4.85

0.99

.82

1
48
32
81

1
3
1
8
14
20
16
18
81

Table 7. Factors associated with aGVHD Development
Factors
Mismatched
CBU
(at 6 loci)
Yes
No
Mismatched
CBU
(at 10 loci)
Yes
No
Primary
Disease
Malignant
NonMalignant
Origin of
CBU
International
Domestic
Donor
Maternal
CMV
Positive
Negative
Recipient
Sex
Male
Female
Mismatched
DonorRecipient
Sex
Yes
No

Total
(N=81)

49
32

63
18

32
49

15
66

39
24

55
26

41
39

aGVHD Yes
(N=8)

5
3

6
2

5
3

1
7

4
3

7
1

3
5

aGVHD No
(N=73)

Risk Ratio
(95%CI)
1.09 (0.28-4.24)

P

0.86 (0.19-3.89)

0.57

2.55 (0.65-9.94)

0.15

0.63 (0.08-4.73)

0.54

0.82 (0.20-3.35)

0.54

3.31 (0.43-25.52)

0.20

0.59 (0.15-2.29)

0.34

0.61

44
29

57
16

27
46

14
59

35
21

48
25

38
35
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Table 8. Factors Associated with Achievement of Engraftment
Factors

Mismatched
CBU
(at 6 loci)
Yes
No
Mismatched
CBU
(at 10 loci)
Yes
No
Primary
Disease
Malignant
NonMalignant

Total
(N=82)

50
32

64
18

33
49

Engraftment
Achievement
No (N=3)

2
1

2
1

1
2

Engraftment
Achievement
Yes (N=79)

Risk Ratio
(95% CI)

P

1.28 (0.12-13.54)

0.66

0.56 (0.05-5.86)

0.53

0.74 (0.07-7.86)

0.64

48
31

62
17

32
47
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Figure 1. Cause of Death of CBU Transplant Recipients
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